MADISON (WKOW) -- By the year 2050, it is estimated that 115 million people worldwide will have Alzheimer’s disease.
There is a desperate need for effective treatments in Alzheimer’s. Researchers are now shining a spotlight on the connection between sleep and slowing the effects of Alzheimer’s.
On Wednesday , Wake Up Wisconsin anchor Brandon Taylor sat down for an interview with Dr. Steven Targum.
Dr. Targum consults widely to the pharmaceutical industry in the areas of psychiatric disorders, clinical trial methodologies, protocol design, study surveillance strategies, study analysis, and the progression of new drug candidates from concept to approval to launch.
Alzheimer's is a growing crisis in the United States and research has identified a correlation between Alzheimer’s disease and poor sleep. Sleep disturbances are seen in 63% of patients with subtle dementia and research shows that poor sleep is directly related to cognitive decline.
A new investigative Alzheimer’s trial, ReCOGNITION, is a Phase 2 clinical trial for which participants are needed. The ReCOGNITION study is being conducted at approximately 75 research centers across the United States. Researchers are seeking patients aged 60 to 85 who have been diagnosed with mild dementia due to Alzheimer’s. Participants will be seen by a doctor and will receive all study-related care and medication at no cost.
Locally, there is a clinical trial site at Dean Foundation for Health Research Education on Allen Blvd.
Click on the video link above to watch the full interview.